Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse

Inclusion Criteria

• •Age \> 12 months and \< 25 years
• •Measurable disease
• •Score of Lansky \> 30 or World Health Organization (WHO) score \< 2
• •Life expectancy \> 2 months
• •Satisfactory hematologic conditions:
• •* Polynuclear neutrophiles \> 1 X 10\^9/l.
• •* Platelets \> 100 X 10\^9/l or \> 50 X 10\^9 in the event of medullary invasion.
• •Creatinine \< 1.5 of normal for age or clearance \> 70 ml/min/1.73 m2
• •Normal hepatic function:
• •* Bilirubin \< 3 N
• •* ASAT and ALAT \< 2,5 N).
• •Absence of toxicity of bodies (Rank \> 2 according to coding National Cancer Institute-Common Toxicity Criteria \[NCI-CTC\] version 2.0)
• •Absence of antecedent of hematuric cystitis to repetition
• •Written consent, signed by the patient or the two parents or holder(s) of the parental authority of the minor subjects